Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 159.9 EUR 3% Market Closed
Market Cap: 31.1B EUR

EV/EBITDA
Enterprise Value to EBITDA

21.1
Current
15.3
Median
12.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
21.1
=
Enterprise Value
31.5B EUR
/
EBITDA
1.5B EUR
Market Cap EV/EBITDA
BE
Ucb SA
XBRU:UCB
30.4B EUR 21.1
US
Eli Lilly and Co
NYSE:LLY
699.1B USD 33.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 12.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 13.3
CH
Roche Holding AG
SIX:ROG
211.2B CHF 9.6
CH
Novartis AG
SIX:NOVN
184.2B CHF 10.3
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP 131
US
Merck & Co Inc
NYSE:MRK
193.3B USD 8.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
133.5B USD 7.3
EBITDA Growth EV/EBITDA to Growth
BE
Ucb SA
XBRU:UCB
Average EV/EBITDA: 395.9
21.1
29%
0.7
US
Eli Lilly and Co
NYSE:LLY
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
15
2-Years Forward
EV/EBITDA
11.9
3-Years Forward
EV/EBITDA
9.9